Top Markets
Coin of the day
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
Rankning i aktier #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Aktiekurs
$1.81
Senast synkroniserad: 2026-08-21
Marknadsvärde
$77.00M
Förändring (1 dag)
1.30%
Förändring (1 år)
-23.63%
Land
US
Handel Annovis Bio, Inc. (ANVS)

Kategori

Aktiekurshistorik för Annovis Bio, Inc. (ANVS)
Högsta slutkurs: $1.82 den 2026-08-01

Lägsta slutkurs: $7.71 den 2020-01-01
Aktiekurshistorik för Annovis Bio, Inc. från 2020 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) -38.81%
2025 -26.28%
2024 -55.51%
2023 0.70%
2022 -41.39%
2021 233.32%
2020 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH